A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Phase 3
Completed
- Conditions
- Multiple SclerosisWalking Impairment
- Interventions
- Drug: ADS-5102, 274 mg
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 424
- Registration Number
- NCT03567057
- Locations
- 🇨🇦
Adamas Clinical Site, Québec City, Quebec, Canada
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Phase 3
Completed
- Conditions
- Walking ImpairmentMultiple Sclerosis
- Interventions
- Drug: ADS-5102, 137 mgOther: PlaceboDrug: ADS-5102, 274 mg
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 558
- Registration Number
- NCT03436199
- Locations
- 🇺🇸
Admas Clinical Site, Detroit, Michigan, United States
🇨🇦Adamas Clinical Site, Quebec City, Quebec, Canada
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Phase 2
Completed
- Conditions
- Walking ImpairmentMultiple Sclerosis
- Interventions
- Other: Placebo
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02471222
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Phase 3
Completed
- Conditions
- DyskinesiaLevodopa-Induced Dyskinesia (LID)Parkinson's Disease (PD)
- Interventions
- Other: Placebo
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT02274766
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Phase 3
Completed
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's Disease (PD)Dyskinesia
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT02202551
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
Phase 3
Terminated
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02153632
- Locations
- 🇪🇸
Hospital General de Cataluna, Barcelona, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
Phase 3
Terminated
- Conditions
- Parkinson's DiseaseLevodopa Induced Dyskinesias (LID)
- Interventions
- First Posted Date
- 2014-06-03
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT02153645
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Phase 3
Completed
- Conditions
- Levodopa Induced Dyskinesia (LID)Parkinson's DiseaseDyskinesia
- Interventions
- Other: Placebo
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT02136914
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
Phase 2
Completed
- Conditions
- Levodopa Induced DyskinesiaParkinson's DiseaseDyskinesia
- Interventions
- Drug: ADS-5102 (extended release amantadine HCl)
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT01397422
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Adamas Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT00979251
- Locations
- 🇸🇬
Adamas Investigational Site, Singapore, Singapore
🇦🇺Adamas Investigative Site, Parkville, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath